ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TWST vs RGEN // EV/EBITDA & P/E VALUATION

Twist Bioscience Corporation (NASDAQ) VS. Repligen Corporation (NASDAQ) • 15-METRIC TALLY: TWST 5 — RGEN 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TWST VS. RGEN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TWST RGEN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 94.20% 88.20% +6.00 TWST /gross-margins <GO>
Return on Invested Capital (ROIC) -11.70% 2.30% -14.00 RGEN /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 95.0x — TIE /valuation <GO>
Free Cash Flow Yield -0.66% 0.88% -1.54 RGEN /fcf-yield <GO>
Operating Margin -4.20% 1.80% -6.00 RGEN /operating-margins <GO>
Net Profit Margin -2.40% 1.60% -4.00 RGEN /net-margins <GO>
Revenue Growth (YoY) 16.50% -3.30% +19.80 TWST /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 26.00 9.31 +16.69 TWST /balance-sheet <GO>
Piotroski F-Score Quality 6/9 8/9 -2.00 RGEN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 57.2 56.7 +0.50 TWST /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.98 1.04 -0.06 RGEN /macro-sensitivity <GO>
Forward P/E Multiple 21.0x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $11.50B $10.69B $805.4M TWST /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TWST REV RGEN REV TWST GROSS % RGEN GROSS % TWST FCF RGEN FCF
FY 2025 $0 $0 — — -$75.6M $93.9M
FY 2024 $0 $0 — — -$69.2M $149.7M
FY 2023 $0 $0 — — -$142.5M $113.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TWST // BETA 0.98
RGEN // BETA 1.04